US 10064923
Therapeutic cancer vaccines derived from a novel dendritic cell line
granted A61KA61K2039/80A61K2239/48
Quick answer
US patent 10064923 (Therapeutic cancer vaccines derived from a novel dendritic cell line) held by DCPRIME B.V. expires Mon Aug 30 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- DCPRIME B.V.
- Grant date
- Tue Sep 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 30 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 3
- CPC classes
- A61K, A61K2039/80, A61K2239/48, A61K40/19, A61K40/24